What is the average price target for STRIDE INC (LRN) stock?
9 analysts have analysed LRN and the average price target is 128.01 USD. This implies a price increase of 43.91% is expected in the next year compared to the current price of 88.95.
NYSE:LRN • US86333M1080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for STRIDE INC (LRN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-28 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-28 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-21 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-12-17 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-29 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-29 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-10-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-24 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-29 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-04-30 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-04-28 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-17 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-04-01 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-03-14 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-03-11 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-30 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-01-29 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-01-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-27 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-17 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-12-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-10-29 | Citigroup | Maintains | Neutral -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.837B 8.93% | 2.04B 11.03% | 2.405B 17.90% | 2.554B 6.18% | 2.675B 4.74% | 2.808B 4.97% | 3.023B 7.66% | 3.158B 4.47% | |
| EBITDA YoY % growth | 275.857M 8.37% | 359.283M 30.24% | 534.241M 48.70% | 605.3M 13.30% | 633.21M 4.61% | 622.19M -1.74% | 857.59M 37.83% | N/A | |
| EBIT YoY % growth | 165.499M 5.66% | 249.6M 50.82% | 419.572M 68.10% | 489.53M 16.67% | 520.06M 6.24% | 566.88M 9.00% | 637.82M 12.51% | 679.02M 6.46% | |
| Operating Margin | 9.01% | 12.23% | 17.44% | 19.17% | 19.44% | 20.19% | 21.10% | 21.50% | |
| EPS YoY % growth | 2.96 17.00% | 4.67 57.77% | 6.02 28.91% | 7.39 22.73% | 7.88 6.63% | 8.64 9.62% | N/A | N/A |
All data in USD
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.06 2.00% | 1.66 60.82% | 1.33 -4.77% | 2.46 -1.63% | 2.14 3.68% | 1.94 17.07% |
| Revenue Q2Q % growth | 635.81M 3.66% | 647.22M -0.98% | 653.05M 5.18% | 669.27M 6.02% | 666.83M 4.88% | 678.1M 4.77% |
| EBITDA Q2Q % growth | 165.5M -23.11% | 149.47M -35.30% | 118.97M 21.13% | 190.85M -7.82% | 176.26M 6.50% | 159.26M 6.55% |
| EBIT Q2Q % growth | 135.95M 3.95% | 119.43M 2.65% | 84.84M 22.99% | 150.29M 2.34% | 145.34M 6.91% | 126.86M 6.22% |
All data in USD
9 analysts have analysed LRN and the average price target is 128.01 USD. This implies a price increase of 43.91% is expected in the next year compared to the current price of 88.95.
STRIDE INC (LRN) will report earnings on 2026-04-27, after the market close.
The consensus EPS estimate for the next earnings of STRIDE INC (LRN) is 2.06 USD and the consensus revenue estimate is 635.81M USD.
The number of analysts covering STRIDE INC (LRN) is 9.